<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ursodeoxycholic acid &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/ursodeoxycholic-acid/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 27 Oct 2026 06:56:28 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>ursodeoxycholic acid &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Liver Injury During Lung Cancer Immunotherapy Leaves Doctors Unsure Whether a Hidden Bile Duct Disease Was to Blame</title>
		<link>https://bioengineer.org/liver-injury-during-lung-cancer-immunotherapy-leaves-doctors-unsure-whether-a-hidden-bile-duct-disease-was-to-blame/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 06:56:28 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[AMA-M2]]></category>
		<category><![CDATA[atezolizumab]]></category>
		<category><![CDATA[cholangiopathy]]></category>
		<category><![CDATA[cholestatic liver injury]]></category>
		<category><![CDATA[combined small cell lung cancer]]></category>
		<category><![CDATA[EGFR L858R]]></category>
		<category><![CDATA[furmonertinib]]></category>
		<category><![CDATA[immune checkpoint inhibitor]]></category>
		<category><![CDATA[immune-related adverse events]]></category>
		<category><![CDATA[IMpower133]]></category>
		<category><![CDATA[primary biliary cholangitis]]></category>
		<category><![CDATA[ursodeoxycholic acid]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=460691</guid>

					<description><![CDATA[A case report describes cholestatic liver injury during atezolizumab therapy for EGFR-mutant combined small cell lung cancer, with AMA-M2 positivity raising the possibility of underlying primary biliary cholangitis that could not be confirmed without baseline serology or biopsy.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">460691</post-id>	</item>
	</channel>
</rss>
